GoodRx Holdings (GDRX) Receivables - Net (2019 - 2026)

GoodRx Holdings (GDRX) has 8 years of Receivables - Net data on file, last reported at $232.7 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net rose 45.34% year-over-year to $232.7 million; the trailing twelve-month figure through Mar 2026 stood at $232.7 million (up 45.34% YoY), and the FY2025 full-year result was $235.7 million, up 61.54% from the prior year.
• Receivables - Net eased to $232.7 million in Q1 2026, from $235.7 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $235.7 million in Q4 2025 to a low of $116.4 million in Q1 2023.
• A 5-year average of $152.6 million and a median of $143.6 million in 2023 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net jumped 65.7% in 2022 and slipped 5.55% in 2023, its largest moves.
• Tracing GDRX's Receivables - Net over 5 years: stood at $117.1 million in 2022, then rose by 22.59% to $143.6 million in 2023, then advanced by 1.62% to $145.9 million in 2024, then soared by 61.54% to $235.7 million in 2025, then dropped by 1.28% to $232.7 million in 2026.
• Business Quant data shows GDRX's Receivables - Net at $232.7 million in Q1 2026, $235.7 million in Q4 2025, and $203.7 million in Q3 2025.